Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1201 in Refractory Autoimmune Diseases
NCT07105735Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RN1201 in autoimmune disease, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Treatment-Emergent Adverse Events at 12 months and Dose-Limiting Toxicities at 28 days. Started Aug 2025; status: recruiting.
02
Drugs
RN1201
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07105735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105735.